















## Day 180 follow-up



- Any sites that are open to flu will complete day 180 follow-up at their site, this has been included in the site payment fee with the SoECAT.
- For sites that are not open to flu, follow-up will be completed by ICNARC as before.

### **CAPA Consent re-training**



- An email was sent to you last year on the consent re-training CAPA (corrective and preventative action) form.
- If any items need to be completed by your site, please remember to acknowledge the initial email and complete the consent re-training log which can be found <a href="https://example.com/here">here</a>.

### **Monitoring visits**



• Our study monitors, Lindsay, Ahmad, Catherine and Walton are prioritising on site visits and will get in touch with you to arrange a visit.

## **Cysteamine domain**



- The cysteamine domain is open in both the pandemic and non-pandemic strata.
- In order to open this domain at your site we require a signed domain choice page, approval for AM028, 29, 35 & 36 and training logs which can be found <a href="mailto:here">here</a>. Once these are in place, please request an order form by sending an email to <a href="mailto:ukremap-cap@icnarc.org">ukremap-cap@icnarc.org</a>

# Easter Break closure dates

Imperial
College is
closed from
6<sup>th</sup> April and is
back open on
the 13th April.

However, the team will be available by email at this time for urgent queries or problems:

ukremapcap@icnarc.o

rg

Thank you to all the sites who have recruited to the influenza stratum!

51 sites currently open to influenza stratum

25 patients recruited

We are still keen to open sites to the influenza stratum. There is a possibility that there may be an outbreak of influenza B which has been seen in other European countries. Bird flu is also a possibility. Though the current strain is not airborne there is a possibility that the strain could mutate thus we need to be ready as the flu platform trial for a potential second wave and future flu seasons.

All influenza documentation including training, PIS/ICF and protocols can be found on the <u>influenza</u> <u>trial page</u> of our website.

Monthly Q&A next session
Wednesday 26<sup>th</sup> April 2023 at
11:00 – 12:00

Please follow the **zoom link** to join.

Meeting ID: **950 8092 5035** 

Passcode: C3E%u3

## **Ordering Baloxavir**

- Before ordering, your site must be active to the antiviral domain (received green light for this domain).
- Please then email the study team for the Baloxavir order form - <u>ukremap-</u> <u>cap@icnarc.org</u>
- Once the order form is complete, please return to the study team, who will provide the order form to Roche.
- Once the stock has been received at your site, please inform the central study team who will turn on the intervention for randomisation.
- Please ensure your site follow your local accountability procedures and the stock is logged on your local pharmacy inventory and accountability logs.
- For returned/expired stock please contact the study team at ukremap-cap@icnarc.org for instructions and approval of destruction.

### The REMAP-CAP influenza domain is almost open to Paediatric sites!

- The eCRF update is in the final stages and in preparation for this we have organised a Paediatric Q&A.
- We hope to provide sites recruiting children with more information on the trial to allow them to start planning recruitment and provide space for any questions that you may have, please see details on this below.

## Site set-up

- For new sites wishing to set up, we will need all training and documentation can be found on our website at the <u>Influenza Paediatrics</u>
   Page.
- All staff working on REMAP-CAP will need to provide GCPs, CVs, training logs and delegation log.
- Sites will also complete an SIV Documents that will be covered
   during the SIV can be found <u>here</u> if
   you would like to take a look
   beforehand.

## **Upcoming webinar**

Follow the **zoom link** to join.


Date: Wednesday 29th March

Time: **12:30 – 13:30** 

Meeting ID: **961 2697 3815** 


Passcode: ^@9GrT

# REMAP-CAP league table: Pandemic



# REMAP-CAP league table: non-pandemic

We would like to say a HUGE thank you to all participating sites!







#### **MILESTONES 2022 - 2023**

#### **APRIL 22 2022**

1<sup>st</sup> patient randomized to updated Immunoglobulin domain.

#### JUNE 17 2022

Vitamin C domain paused for nonpandemic patients due to results from the LOVIT trial.

#### JULY 16 2022

Vitamin C domain paused for pandemic patients due to hitting a statistical trigger.

#### AUGUST 28 2022

10,000<sup>th</sup> patient randomised to the study worldwide.

#### NOVEMBER 02 2022

First influenza patient recruited.

#### **JANUARY 26 2022**

Baloxavir opened to sites

#### JUNE 16\_2022

ACE2RAS domain closed for moderate state patients.

#### JULY 06 2022

'Continuation of the therapeutic dose anticoagulation' intervention of the Anticoagulation domain was closed.

#### JULY 18 2022

Vitamin C domain closed due to results from the LOVIT trial.

#### OCTOBER 21\_2022

REMAP-CAP were selected by the NIHR as the platform trial to evaluate therapeutic interventions for influenza.

#### JANUARY 09\_2023

Simvastatin Domain closed to recruitment due to operational futility.

#### TBC

Paediatric CRF open to sites.



